Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: HELLP Syndrome
• MONDO ID: (if available)
• Category: Complex

Research Objectives

Please provide a comprehensive research report on HELLP Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

HELLP syndrome: disease-characteristics research report

Scope. HELLP is an obstetric emergency rather than a classical monogenic disease. The strongest HELLP-specific evidence concerns clinical diagnosis, placental/endothelial pathology, and complement activation; much newer omics literature studies preeclampsia broadly and cannot automatically be generalized to HELLP. Publication dates and URLs are supplied for the principal sources. Where a requested field is unsupported or inapplicable, this is stated explicitly.

Table: This compact table summarizes the best-supported findings for HELLP syndrome across clinical definition, epidemiology, mechanisms, genetics, diagnosis, treatment, prognosis, and research gaps. It is useful as a quick evidence map for building a disease knowledge-base entry.

1. Disease information

HELLP is an acronym for hemolysis, elevated liver enzymes, and low platelet count. It is a pregnancy-associated thrombotic microangiopathic syndrome generally considered a severe phenotype within the preeclampsia spectrum, although hypertension or proteinuria may not be prominent in every presentation. The defining processes are microangiopathic hemolysis, hepatocellular injury, and platelet consumption. Removal of the placenta at delivery is followed by improvement in most true HELP/HELLP-spectrum cases, supporting a placenta-mediated disorder. (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11)

Identifiers and synonyms

• MONDO: MONDO:0008585, HELLP syndrome. Open Targets currently lists no validated associated target for this MONDO disease, underscoring that there is no established single causal gene or approved molecular target. (OpenTargets Search: HELLP syndrome)
• MeSH: D017359, HELLP Syndrome. (NCT01138839 chunk 1)
• OMIM/Orphanet: no dedicated Mendelian OMIM entry or well-supported monogenic Orphanet disease identity was established in the retrieved evidence.
• ICD: coding varies by jurisdiction and trimester; HELLP is usually coded within preeclampsia/severe preeclampsia categories rather than as a universally consistent standalone code. Local ICD-10-CM/ICD-11 release validation is required before database loading.
• Synonyms: HELLP syndrome; hemolysis–elevated liver enzymes–low platelet count syndrome; HELLP variant of severe preeclampsia; complete/classic HELLP. “Partial HELLP” is older and inconsistent terminology, often overlapping preeclampsia with severe features.
• Category: complex, multifactorial pregnancy disorder; acquired, placenta-associated thrombotic microangiopathy.

This report synthesizes aggregated disease-level evidence from reviews, cohorts, meta-analysis, and trial registrations. It is not derived from an individual EHR.

2. Etiology, risk, and protection

Causal framework

No single necessary and sufficient cause is known. The prevailing causal model is: abnormal placentation and/or placental stress → ischemia/hypoxia and trophoblast injury → release of antiangiogenic and inflammatory factors → systemic endothelial activation → platelet aggregation/consumption, red-cell fragmentation, hepatic sinusoidal microvascular injury, and multiorgan dysfunction. Delivery removes the principal upstream organ but does not instantly reverse established endothelial and coagulation injury. (burwick2022complementactivationand pages 7-11)

Risk factors

HELLP-specific quantitative risk-factor evidence is less robust than for preeclampsia. Clinically relevant risk enrichment includes prior HELLP or preeclampsia, chronic hypertension, antiphospholipid syndrome, multifetal pregnancy, obesity, diabetes, renal disease, autoimmune disease, advanced maternal age, and assisted reproduction. These are susceptibility factors, not deterministic causes. Socioeconomic disadvantage and reduced access to prenatal care can delay recognition and increase severe outcomes; these are health-system/environmental modifiers rather than direct molecular causes. A 2024 review notes disproportionate preeclampsia morbidity across racial and socioeconomic groups, but these patterns should not be interpreted as biological race effects. (ng2024biomarkersandpoint pages 1-2)

A mechanistically informative gene–environment observation is the interaction between obesity and complement activation: in a prospective preeclampsia cohort, BMI >30 kg/m² plus elevated early-pregnancy Bb produced adjusted odds ratio 10.0 (95% CI 3.3–30), while obesity plus elevated C3a produced adjusted odds ratio 8.8 (95% CI 3–24). This is preeclampsia-spectrum—not HELLP-specific—evidence. (burwick2022complementactivationand pages 15-19)

Protective factors and prevention

There is no proven HELLP-specific vaccine, dietary intervention, or protective genotype. In patients at elevated preeclampsia risk, guideline-based low-dose aspirin started early in pregnancy moderately reduces preeclampsia risk and may consequently reduce some HELLP events, but it is not a guaranteed HELLP preventive treatment. Calcium supplementation is relevant in populations with low dietary calcium under applicable obstetric guidance. Blood-pressure optimization, management of diabetes/renal disease, smoking avoidance, healthy prepregnancy weight, and early prenatal surveillance are reasonable risk-reduction strategies, not established disease-specific cures. (ng2024biomarkersandpoint pages 1-2, cao2024placentaloriginsof pages 1-2)

3. Phenotypes

HELLP is adult-onset by definition because it occurs during pregnancy or puerperium. It is usually acute and progressive over hours to days, most often in the third trimester and frequently before 36 weeks; it can first manifest postpartum. A contemporary trial synopsis reports malaise and right-upper-quadrant pain in approximately 90% each, although these figures derive from cited historical literature rather than the trial itself. (NCT07377786 chunk 1)

Quality-of-life research using HELLP-specific EQ-5D/SF-36 instruments is sparse. Immediate impact is severe—hospitalization, ICU care, urgent delivery, pain, loss of pregnancy autonomy, and neonatal intensive care. Longer-term impacts may include post-traumatic stress, anxiety, grief after fetal loss, and cardiovascular surveillance burden, but precise phenotype-specific frequencies were not established in the retrieved sources.

4. Genetic and molecular information

No established causal gene

HELLP does not follow Mendelian inheritance, and routine designation of any variant as “pathogenic for HELLP” is not justified. Open Targets reports zero validated disease-target associations for MONDO:0008585. Consequently, WES, WGS, gene panels, CMA, karyotyping, FISH, mitochondrial DNA, and repeat-expansion testing are not routine HELLP diagnostics. (OpenTargets Search: HELLP syndrome)

Susceptibility evidence

Complement-regulatory variants may define a subset with heightened complement activation. Across heterogeneous preeclampsia/HELLP studies, CD46/MCP variants occurred in about 8% of 264 cases, CFH mutations in 1.2%, and CFI mutations in 4.2%. Reported functional variants include CFH p.Arg303Gln, affecting C3b binding/decay acceleration, and CFI p.Arg345Gln (c.1034G>A), with defective C3b/C4b cofactor activity. In one very small series, complement variants or CFHR deletions occurred in 5/11 (45%) HELLP cases and 3/14 (21%) severe-feature cases; homozygous CFHR1–CFHR3 or CFHR1 deletions could favor C5b-9 formation. These estimates require replication and are not population penetrance values. (burwick2022complementactivationand pages 11-15, burwick2022complementactivationand pages 15-19)

The relevant variants are germline susceptibility alleles/deletions, not somatic mutations. Penetrance is incomplete; paternal/fetal complement status is generally unmeasured. No established protective allele, anticipation, germline mosaicism, founder mutation, carrier frequency, or consanguinity effect is known for HELLP. (burwick2022complementactivationand pages 15-19)

Fetal HADHA/HADHB fatty-acid-oxidation defects are strongly linked to acute fatty liver of pregnancy and have historically been associated with some HELLP-like maternal liver disease. They should not be entered as common causal HELLP genes. If profound maternal hypoglycemia, hepatic failure, or a neonatal fatty-acid oxidation disorder raises concern, targeted maternal–fetal metabolic/genetic evaluation may be appropriate.

Epigenetics and chromosomal abnormalities

Preeclampsia studies report placental DNA-methylation and regulatory-RNA changes, but no HELLP-specific epigenetic lesion is clinically validated. No recurrent aneuploidy, translocation, inversion, or pathogenic copy-number change defines HELLP.

5. Environmental, lifestyle, and infectious information

No toxin, radiation exposure, pollutant, occupational agent, bacterium, virus, fungus, or parasite is established as a direct cause. Infection and inflammatory stress can activate complement and endothelium and may serve as nonspecific triggers in susceptible pregnancies, but HELLP is not infectious or transmissible. Lifestyle associations largely track preeclampsia risk; no evidence supports alcohol, smoking, diet, or exercise as a singular HELLP cause. Limited prenatal access is an important real-world determinant of delayed diagnosis and worse outcome. (ng2024biomarkersandpoint pages 1-2, veraponce2025globalprevalenceof pages 1-2)

6. Mechanism and pathophysiology

Causal chain and hierarchy

1. Upstream placental dysfunction: deficient spiral-artery remodeling and impaired uteroplacental perfusion produce hypoxia, oxidative stress, inflammation, apoptosis/necrosis, and trophoblast shedding.
2. Angiogenic imbalance: stressed trophoblasts release excess soluble FLT1 (sFlt-1), which sequesters VEGF and PlGF; soluble endoglin may add TGF-β pathway antagonism. Reduced VEGF/PlGF signaling promotes systemic endothelial dysfunction, hypertension, proteinuria, and glomerular endotheliosis. (cao2024placentaloriginsof pages 1-2, burwick2022complementactivationand pages 7-11)
3. Complement amplification: normal pregnancy has regulated complement activation. In HELLP/preeclampsia, activation exceeds regulation; placental C4d and terminal C5b-9 deposits increase. C5a stimulates monocytes/trophoblasts to increase sFlt-1, and C5b-9 can injure trophoblasts, creating a feed-forward angiogenic–complement loop. (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11)
4. Systemic endothelial/TMA phase: endothelial activation exposes prothrombotic surfaces; platelet adhesion and aggregation release thromboxane and serotonin, promoting vasospasm and further platelet consumption. Erythrocytes fragment while traversing narrowed, fibrin-rich microvessels, causing schistocytes, LDH elevation, low haptoglobin, and bilirubin elevation. (NCT07377786 chunk 1)
5. Organ injury: hepatic sinusoidal obstruction, ischemia, hemorrhage, and hepatocyte injury elevate AST/ALT and cause RUQ pain; severe cases develop subcapsular hematoma or rupture. Renal endothelial injury causes proteinuria/AKI; cerebral and pulmonary endothelial dysfunction can cause seizures, stroke, or edema.
6. Resolution: placental delivery stops the principal upstream stimulus, but laboratory abnormalities can transiently worsen postpartum before recovering. Persistence or worsening beyond the expected postpartum window raises concern for TTP, complement-mediated aHUS, CAPS, or another TMA. (markin2024thromboticmicroangiopathyin pages 5-6, burwick2022complementactivationand pages 7-11)

Suggested GO biological-process terms: response to hypoxia (GO:0001666), angiogenesis (GO:0001525), regulation of complement activation (GO:0030449), complement activation (GO:0006956), endothelial-cell activation, platelet activation (GO:0030168), coagulation (GO:0050817), inflammatory response (GO:0006954), apoptotic process (GO:0006915), oxidative-stress response (GO:0006979).

Cell Ontology suggestions: trophoblast cell (CL:0000351), syncytiotrophoblast, extravillous trophoblast, vascular endothelial cell (CL:0000115), monocyte (CL:0000576), macrophage (CL:0000235), neutrophil (CL:0000775), platelet (CL:0000233), erythrocyte (CL:0000232), hepatocyte (CL:0000182), glomerular endothelial cell.

Subcellular/biochemical compartments: extracellular complement cascade; endothelial plasma membrane; platelet granules; mitochondrial oxidative-stress pathways; hepatocyte cytoplasm; terminal complement membrane-attack complex. Suggested GO-CC: extracellular region (GO:0005576), plasma membrane (GO:0005886), membrane attack complex (GO:0005579), mitochondrion (GO:0005739).

Molecular profiling and advanced technologies

The 2024 placental multi-omics review identifies FLT1 as a reproducible preeclampsia signature gene and describes transcriptomic, proteomic, fetal-GWAS, and single-cell evidence implicating trophoblast and placental vascular cell states. It also stresses substantial interstudy inconsistency, small samples, and inadequate subtype validation. These findings are promising but mostly not HELLP-specific. (cao2024placentaloriginsof pages 1-2)

Human/in-vitro/animal complement evidence is more HELLP-relevant: C5a stimulation increases trophoblast sFLT1 transcripts and reduces PlGF; placental C5b-9 correlates with sFLT1 protein (r=0.59, P=0.01); C5a impairs trophoblast migration/tube formation and C5a-receptor inhibition reverses these effects. Mouse experiments show C5a-driven monocyte sFlt-1 production, placental dysfunction, and fetal death, preventable with C5aR inhibition. (burwick2022complementactivationand pages 11-15)

In active severe preeclampsia, urinary C5a rose approximately fivefold and C5b-9 more than fourfold; urinary C5b-9 was detected in 96% of severe cases in cited cohorts. These remain investigational biomarkers and were not validated as standalone HELLP tests. (burwick2022complementactivationand pages 15-19)

There is no validated HELLP clinical diagnostic based on RNA-seq, proteomics, metabolomics, lipidomics, spatial transcriptomics, cfDNA, or CRISPR screening.

7. Anatomical structures affected

• Primary: placenta/uteroplacental circulation—chorionic villi, syncytiotrophoblast, extravillous trophoblast, decidua, spiral arteries. Suggested UBERON: placenta (UBERON:0001987), decidua, uterine artery.
• Defining maternal organ: liver—hepatic sinusoids, periportal parenchyma, subcapsular region. Suggested UBERON: liver (UBERON:0002107).
• Hematovascular: systemic microvascular endothelium, erythrocytes, platelets, coagulation system.
• Secondary: kidney/glomerulus (UBERON:0002113), brain (UBERON:0000955), lung (UBERON:0002048), heart/circulation.
• Fetal: fetal placenta and fetus are secondarily affected through uteroplacental insufficiency and medically indicated prematurity.

Lateralization is generally not applicable. Hepatic hematoma or rupture may be focal and is often reported in the right lobe, but no defining laterality exists.

8. Temporal development

Onset is typically acute after 20 weeks, predominantly in the third trimester; cases may develop in the immediate postpartum period. Symptoms can be vague initially and laboratory deterioration rapid. The most clinically useful stages are not formal disease stages but: suspected disease, complete/partial laboratory syndrome, severe maternal or fetal complication, delivery, and postpartum resolution. (markin2024thromboticmicroangiopathyin pages 5-6, NCT07377786 chunk 1)

Serial platelet count, AST/ALT, LDH, bilirubin, creatinine, coagulation studies, urine output, blood pressure, symptoms, and fetal status are crucial. A prospective 2023–2025 cohort, NCT06758960, followed platelets, LDH, and liver enzymes daily for ten days around delivery, illustrating current interest in biological progression/regression. (NCT06758960 chunk 1)

Typical recovery begins after delivery and often occurs within approximately one week. Failure to improve within 48–72 hours, or worsening renal-predominant TMA, should prompt urgent reevaluation. HELLP is generally self-limited after pregnancy rather than lifelong, but recurrence and long-term cardiometabolic risk remain.

9. Inheritance and population

A 2025 systematic review/meta-analysis of nine HELLP studies (133,611 participants) estimated global prevalence at 0.39% (95% CI 0.16–0.72); the authors explicitly cautioned that the estimate rests on a small study pool. Higher prevalence was observed in lower-income regions, likely reflecting differences in risk structure, diagnostic criteria, and healthcare access. (veraponce2025globalprevalenceof pages 1-2)

Other sources commonly cite approximately 0.1–0.9% of pregnancies, with higher occurrence among severe preeclampsia. NCT04103489 uses 0.1–0.2%, while NCT07377786 cites up to 0.9%, demonstrating criterion and population heterogeneity. (NCT07377786 chunk 1, NCT04103489 chunk 1)

The affected pregnant patient is female; fetal/neonatal consequences affect both sexes. This is multifactorial/polygenic susceptibility rather than AD, AR, X-linked, or mitochondrial inheritance. No established penetrance, anticipation, carrier frequency, founder effect, or consanguinity effect exists. Family history of preeclampsia may increase risk but does not constitute simple inheritance.

Recurrence in a later pregnancy is clinically meaningful, but exact rates vary by study, gestational age, and whether recurrence means HELLP specifically or any hypertensive disorder. Prior HELLP warrants preconception counseling, low-dose aspirin when indicated, baseline renal/liver/platelet assessment, and high-risk obstetric surveillance.

10. Diagnostics

Core laboratory diagnosis

The widely used Tennessee complete-HELLP criteria require all three components:

1. Microangiopathic hemolysis: abnormal peripheral smear/schistocytes, low haptoglobin, elevated LDH; bilirubin >1.2 mg/dL may support hemolysis.
2. Liver injury: AST ≥70 IU/L or aminotransferases at least twice the upper reference limit.
3. Platelets <100 × 10⁹/L.

LDH ≥600 IU/L is commonly used. Thresholds and whether LDH is assigned to hemolysis or liver injury vary by framework. (markin2024thromboticmicroangiopathyin pages 5-6, NCT07377786 chunk 1)

The Mississippi classification grades severity principally by nadir platelet count: class 1 ≤50 × 10⁹/L, class 2 >50 to ≤100 × 10⁹/L, and class 3 >100 to ≤150 × 10⁹/L, together with biochemical evidence of liver injury/hemolysis. Laboratories and guidelines should retain their exact local definitions because published cutoffs differ.

Recommended work-up

CBC with serial platelets; peripheral smear; LDH; haptoglobin; total/direct bilirubin; AST/ALT; creatinine/electrolytes; urinalysis/protein quantification; PT, aPTT and fibrinogen if bleeding/DIC is suspected; blood type and crossmatch; frequent blood pressure and neurologic assessment; fetal heart-rate monitoring and obstetric ultrasound as clinically indicated. Imaging is not required for diagnosis, but urgent liver ultrasound, CT, or MRI is appropriate for severe RUQ/shoulder pain, shock, falling hematocrit, or suspected hematoma/rupture.

PlGF or sFlt-1/PlGF can aid assessment of suspected preeclampsia in some jurisdictions but does not replace HELLP blood tests. Point-of-care and omics biomarkers remain incompletely validated. (ng2024biomarkersandpoint pages 1-2, cao2024placentaloriginsof pages 1-2)

Differential diagnosis

• TTP: marked thrombocytopenia and neurologic features; severe ADAMTS13 activity deficiency supports TTP. Delivery alone does not resolve it; urgent plasma exchange is required.
• Complement-mediated aHUS: renal-predominant TMA, often postpartum, severe AKI, and failure to resolve after delivery; complement genetics can support but normal testing does not exclude it.
• Acute fatty liver of pregnancy: hypoglycemia, coagulopathy, hyperbilirubinemia, encephalopathy, ammonia elevation, and diffuse hepatic dysfunction are more prominent; overlap occurs.
• DIC: prolonged PT/aPTT, low fibrinogen, markedly increased fibrin-degradation products, usually secondary to abruption, hemorrhage, sepsis, fetal death, or severe HELLP.
• Other: antiphospholipid syndrome/CAPS, lupus flare, viral hepatitis, biliary disease, sepsis, immune thrombocytopenia, gestational thrombocytopenia, drug-induced liver injury.

True HELLP generally improves after delivery, whereas persistent postpartum TMA should trigger ADAMTS13 testing, hemolysis reassessment, nephrology/hematology input, and evaluation for aHUS. (burwick2022complementactivationand pages 11-15, markin2024thromboticmicroangiopathyin pages 5-6)

No asymptomatic population HELLP screen, newborn screen, carrier screen, or cascade genetic test is recommended.

11. Outcome and prognosis

HELLP can cause eclampsia, DIC, placental abruption, acute kidney injury, pulmonary edema/respiratory failure, stroke, hepatic hematoma or rupture, hemorrhage, ICU admission, and death. Fetal outcomes are driven largely by placental insufficiency, abruption, fetal distress, growth restriction, and gestational age at indicated delivery; outcomes include NICU admission, acidemia/low Apgar score, stillbirth, and complications of prematurity. (NCT07377786 chunk 1, NCT07377786 chunk 2)

A trial registration cites historical maternal and perinatal mortality as high as 23.1% and 56.9%, respectively. These are not contemporary universal rates and likely reflect selected severe cases and resource-limited settings; they should not be used as baseline prognosis in well-resourced modern care. (NCT07377786 chunk 1)

Most patients recover hematologically and hepatically after delivery. Prognosis worsens with very early gestational age, platelet class 1, DIC, hepatic rupture, stroke, severe AKI, placental abruption, delayed diagnosis, and failure of TMA to resolve postpartum. Survivors of preeclampsia-spectrum disease have increased later cardiovascular, hypertensive, metabolic, and renal risk; postpartum transition to primary care and periodic blood-pressure, lipid, glucose, renal-function, and cardiovascular-risk assessment are warranted.

12. Treatment and real-world implementation

HELLP requires urgent management in a hospital with obstetric, anesthesia, neonatal, transfusion, and critical-care capability.

1. Stabilize: two large-bore IV lines, serial laboratory tests, blood-bank preparation, strict fluid balance, oxygen if needed, and continuous maternal/fetal assessment.
2. Treat severe hypertension: rapid-acting IV labetalol, IV hydralazine, or immediate-release oral nifedipine under obstetric protocols to reduce stroke risk.
3. Prevent/treat seizures: magnesium sulfate unless contraindicated, with dose adjustment/monitoring in renal impairment.
4. Delivery: definitive therapy is delivery after initial maternal stabilization. Immediate delivery is indicated for uncontrolled severe hypertension, eclampsia, DIC, abruption, nonreassuring fetal status, pulmonary edema, progressive renal/hepatic injury, suspected liver rupture, or other instability. Brief delay for antenatal corticosteroids may be considered only in carefully selected stable preterm cases at an appropriate center; HELLP is not ordinarily managed by prolonged expectant care. (ng2024biomarkersandpoint pages 1-2, burwick2022complementactivationand pages 7-11)
5. Route: vaginal delivery is acceptable when obstetrically feasible and timely; cesarean delivery is based on gestational age, cervical status, fetal condition, and urgency—not HELLP alone.
6. Fetal lung maturation: betamethasone or dexamethasone for anticipated preterm birth according to gestational-age guidance. This is distinct from high-dose maternal dexamethasone intended to alter HELLP laboratory recovery.
7. Blood products: red cells for symptomatic anemia/hemorrhage; platelets for active bleeding, very low count, or procedures according to local thresholds; plasma/cryoprecipitate for DIC or factor/fibrinogen deficiency. Transfusion should be individualized.
8. Anesthesia: neuraxial anesthesia depends on platelet count trend, coagulation status, bleeding history, and anesthesiology risk assessment. No single platelet cutoff is universally safe.
9. Postpartum: continue close monitoring because platelets and enzymes may worsen initially; assess hemorrhage, renal function, pulmonary edema, neurologic symptoms, and blood pressure.

Maternal corticosteroid controversy. A phase 3 randomized protocol, NCT01138839, tested IV dexamethasone 10 mg every 12 hours in Mississippi class-1 HELLP, with hospitalization and platelet/liver-enzyme recovery outcomes. The registry notes that an earlier subgroup signal for faster platelet recovery was unplanned. High-dose corticosteroids should therefore not be represented as proven definitive maternal therapy. (NCT01138839 chunk 1)

Complement inhibition. NCT04103489 was a completed, open-label phase 1 study of eculizumab in HELLP at 23–30 weeks, enrolling only three participants and evaluating laboratory change and pregnancy latency. This is biologically plausible because most studied HELLP samples showed alternative-pathway activation suppressible by anti-C5 in vitro, but the study is far too small to establish efficacy or routine use. Eculizumab remains investigational for HELLP; aHUS is a separate approved indication. (NCT04103489 chunk 1)

Suggested NCIt intervention concepts: Therapeutic delivery/induction of labor; cesarean section; magnesium sulfate; antihypertensive therapy; labetalol; hydralazine; nifedipine; betamethasone; dexamethasone; red-blood-cell transfusion; platelet transfusion; fresh-frozen plasma transfusion; cryoprecipitate; eculizumab.

Gene therapy, cell therapy, RNA therapy, CRISPR, immunotherapy other than investigational complement blockade, and genotype-guided pharmacotherapy have no current clinical role.

13. Prevention

• Primary: preconception optimization of chronic hypertension, diabetes, renal disease, obesity, and autoimmune disease; early prenatal care; guideline-based aspirin for high-risk patients; calcium where dietary intake is low.
• Secondary: early recognition through blood-pressure measurement, symptom education, urine assessment, and prompt CBC/liver/hemolysis testing when symptoms or hypertension arise. There is no general-population HELLP biomarker screen.
• Tertiary: immediate stabilization and delivery when indicated; seizure/stroke prevention; transfusion and organ support; postpartum TMA reassessment; cardiovascular and renal follow-up.
• Counseling: explain recurrence risk, warning symptoms (severe headache, visual symptoms, epigastric/RUQ pain, dyspnea, bleeding, reduced fetal movement), aspirin planning, and need for maternal–fetal medicine surveillance.
• Public health: improve prenatal access, emergency referral pathways, laboratory/transfusion capacity, and postpartum follow-up, particularly in low-resource settings where prevalence and severe outcomes are higher. (ng2024biomarkersandpoint pages 1-2, veraponce2025globalprevalenceof pages 1-2)

Vaccination and environmental decontamination are not HELLP-specific preventive measures.

14. Other species and natural disease

No validated naturally occurring veterinary disorder equivalent to the complete human HELLP syndrome was identified. HELLP depends on human pregnancy-specific placentation, maternal spiral-artery remodeling, and obstetric definitions; therefore it is not considered zoonotic, contagious, or transmissible across species. No breed/VBO association is established. Orthologs of complement, angiogenic, and coagulation genes are evolutionarily conserved, permitting mechanistic experiments, but similarity of pathway is not evidence of natural HELLP in animals.

15. Model organisms and experimental systems

No model reproduces the complete human triad, gestational timing, placental pathology, and postpartum resolution with high fidelity.

• Rodent placental-ischemia/reduced uterine perfusion models: reproduce hypertension, endothelial dysfunction, angiogenic imbalance, fetal growth restriction, and sometimes liver/platelet changes. They are useful for upstream placental mechanisms but incompletely reproduce HELLP.
• Complement-dysregulation/antiphospholipid models: C5a can drive monocyte sFlt-1 production, placental dysfunction, and fetal loss; C5aR inhibition prevents selected phenotypes. These support a causal complement–angiogenic link, not a universal complement etiology. (burwick2022complementactivationand pages 11-15)
• C1q-deficient mice: develop preeclampsia-like hypertension, proteinuria, glomerular endotheliosis, oxidative stress, and increased sFlt-1/PlGF ratio; they are placentation/complement models rather than faithful HELLP models.
• BPH/5 mouse: spontaneous preeclampsia-like model in which angiogenic imbalance can precede placental complement deposition; useful for temporal pathway studies.
• In-vitro human trophoblast/endothelial systems: hypoxia and C5b-9 increase trophoblast injury; C5a reduces migration and tube formation and increases sFLT1. Primary trophoblast, placental explant, endothelial coculture, organoid, and placenta-on-chip systems improve human relevance but lack whole-body maternal coagulation, liver, kidney, and fetal physiology. (burwick2022complementactivationand pages 1-7, burwick2022complementactivationand pages 7-11, burwick2022complementactivationand pages 11-15)

Suggested model resources include MGI, RGD, IMSR/MMRRC, GEO/SRA, Cellosaurus, and placental single-cell atlases. No standard MGI “HELLP mouse” should be asserted without model-specific curation.

Recent developments and evidence appraisal

The strongest 2023–2024 advances are: (1) expanding placental single-cell and multi-omic maps, with FLT1 and trophoblast/vascular cell states repeatedly implicated; (2) growing clinical adoption of PlGF and sFlt-1/PlGF testing for suspected preeclampsia, though not a substitute for HELLP criteria; and (3) improved recognition that postpartum nonresolving “HELLP” may instead be TTP or complement-mediated aHUS. The 2024 multi-omics review concludes that placental molecular findings are promising but inconsistent and require larger, standardized, subtype-specific validation. (ng2024biomarkersandpoint pages 1-2, cao2024placentaloriginsof pages 1-2)

The principal translational frontier is complement stratification. Human placental deposition, urinary biomarkers, functional assays, susceptibility variants, in-vitro inhibition, and animal rescue experiments collectively support complement as a biologically credible amplifier in a subset. They do not yet prove that all HELLP is complement-driven or that anti-C5 therapy improves outcomes. The three-participant eculizumab phase-1 experience is hypothesis-generating only. (burwick2022complementactivationand pages 1-7, NCT04103489 chunk 1, burwick2022complementactivationand pages 15-19)

Selected exact source statements

• Burwick and Feinberg, published February 2022, state: “In women who develop preeclampsia and HELLP syndrome, there is a shift towards increased complement activation and decreased complement regulation.” DOI: https://doi.org/10.1016/j.ajog.2020.09.038. (burwick2022complementactivationand pages 1-7)
• Cao, Saxena, and Gray, published 28 August 2024, state: “Transcriptomic studies in bulk placental tissue have identified many dysregulated genes in the PE placenta, including the PE signature gene, Fms-like tyrosine kinase 1 (FLT1).” DOI: https://doi.org/10.3390/ijms25179343. This is preeclampsia-spectrum evidence, not HELLP-specific validation. (cao2024placentaloriginsof pages 1-2)
• Ng et al., published October 2024, state that newer diagnostic and imaging tests “are still in the process of undergoing widespread regulatory adoption, and so are not yet the standard of care.” DOI: https://doi.org/10.1038/s43856-024-00642-4. (ng2024biomarkersandpoint pages 1-2)
• Vera-Ponce et al., published 10 November 2025, report HELLP prevalence “0.39% (95% CI: 0.16%–0.72%),” while cautioning that it derives from only nine studies. DOI: https://doi.org/10.3389/frph.2025.1706009. (veraponce2025globalprevalenceof pages 1-2)

Knowledge-base cautions

1. Do not annotate CFH, CFI, CD46, CFHR1, CFHR3, HADHA, or HADHB as universally causal HELLP genes; evidence supports susceptibility, mechanistic overlap, or differential diagnosis.
2. Do not use sFlt-1/PlGF, complement biomarkers, NLR/PLR, MPV/PDW, proteomics, or transcriptomics as standalone diagnostic criteria.
3. Do not infer TTP or aHUS treatment from a HELLP label without reassessing postpartum trajectory, ADAMTS13, renal severity, and complement-mediated TMA.
4. Delivery remains the definitive placenta-directed treatment; eculizumab and high-dose maternal dexamethasone are investigational/controversial rather than established disease-modifying standards.
5. HELLP-specific PMID capture was incomplete in the retrieved corpus; DOI and ClinicalTrials.gov identifiers are therefore supplied where verified rather than inventing PMIDs.

References

1. (NCT07377786 chunk 1): Esraa Jaheen Ali. Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.. Sohag University. 2026. ClinicalTrials.gov Identifier: NCT07377786

2. (burwick2022complementactivationand pages 7-11): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.

3. (veraponce2025globalprevalenceof pages 1-2): Víctor Juan Vera-Ponce, Joan A. Loayza-Castro, Jhosmer Ballena-Caicedo, Lupita Ana Maria Valladolid-Sandoval, Fiorella E. Zuzunaga-Montoya, and Carmen Inés Gutierrez De Carrillo. Global prevalence of preeclampsia, eclampsia, and hellp syndrome: a systematic review and meta-analysis. Frontiers in Reproductive Health, Nov 2025. URL: https://doi.org/10.3389/frph.2025.1706009, doi:10.3389/frph.2025.1706009. This article has 73 citations.

4. (burwick2022complementactivationand pages 1-7): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.

5. (burwick2022complementactivationand pages 11-15): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.

6. (burwick2022complementactivationand pages 15-19): Richard M. Burwick and Bruce B. Feinberg. Complement activation and regulation in preeclampsia and hemolysis, elevated liver enzymes, and low platelet count syndrome. American Journal of Obstetrics and Gynecology, 226:S1059-S1070, Feb 2022. URL: https://doi.org/10.1016/j.ajog.2020.09.038, doi:10.1016/j.ajog.2020.09.038. This article has 96 citations and is from a highest quality peer-reviewed journal.

7. (NCT04103489 chunk 1): The Use of Eculizumab in HELLP Syndrome. Johns Hopkins University. 2021. ClinicalTrials.gov Identifier: NCT04103489

8. (markin2024thromboticmicroangiopathyin pages 5-6): Л. Б. Маркін, К. Л. Шатилович, С. М. Сергійчук, Г. Я. Кунинець, and М. П. Лисий. Thrombotic microangiopathy in the postpartum period (literature review, clinical case report). Lviv clinical bulletin, pages 84-95, Sep 2024. URL: https://doi.org/10.25040/lkv2024.03.084, doi:10.25040/lkv2024.03.084. This article has 1 citations.

9. (ng2024biomarkersandpoint pages 1-2): Ka Wai Ng, Nandita Chaturvedi, Gerard L. Coté, Stephanie A. Fisher, and Samuel B. Mabbott. Biomarkers and point of care screening approaches for the management of preeclampsia. Communications Medicine, Oct 2024. URL: https://doi.org/10.1038/s43856-024-00642-4, doi:10.1038/s43856-024-00642-4. This article has 53 citations and is from a peer-reviewed journal.

10. (NCT01138839 chunk 1): Dexamethasone Efficacy in HELLP I Syndrome. Universidad del Valle, Colombia. 2009. ClinicalTrials.gov Identifier: NCT01138839

11. (NCT07377786 chunk 2): Esraa Jaheen Ali. Study of Prognostic Values of Platelet Indices and Inflammatory Markers in Patients With HELLP Syndrome.. Sohag University. 2026. ClinicalTrials.gov Identifier: NCT07377786

12. (NCT06758960 chunk 1): Meryem Essafti. Analysis of Biological Progression and Regression of HELLP Syndrome in Time. CHU Mohammed VI Marrakech. 2023. ClinicalTrials.gov Identifier: NCT06758960

13. (cao2024placentaloriginsof pages 1-2): Chang Cao, Richa Saxena, and Kathryn J. Gray. Placental origins of preeclampsia: insights from multi-omic studies. International Journal of Molecular Sciences, 25:9343, Aug 2024. URL: https://doi.org/10.3390/ijms25179343, doi:10.3390/ijms25179343. This article has 36 citations.

14. (OpenTargets Search: HELLP syndrome): Open Targets Query (HELLP syndrome, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.